BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25322876)

  • 1. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
    Ito H; Ando T; Arioka Y; Saito K; Seishima M
    Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice.
    Ito H; Ando T; Ogiso H; Arioka Y; Seishima M
    Cancer Immunol Immunother; 2015 Apr; 64(4):429-36. PubMed ID: 25567751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer.
    Dewan MZ; Vanpouille-Box C; Kawashima N; DiNapoli S; Babb JS; Formenti SC; Adams S; Demaria S
    Clin Cancer Res; 2012 Dec; 18(24):6668-78. PubMed ID: 23048078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists.
    Triozzi PL; Aldrich W; Ponnazhagan S
    Cancer Gene Ther; 2011 Dec; 18(12):850-8. PubMed ID: 21869824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
    Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
    Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
    J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.
    Inaba T; Ino K; Kajiyama H; Yamamoto E; Shibata K; Nawa A; Nagasaka T; Akimoto H; Takikawa O; Kikkawa F
    Gynecol Oncol; 2009 Nov; 115(2):185-92. PubMed ID: 19665763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
    Hou DY; Muller AJ; Sharma MD; DuHadaway J; Banerjee T; Johnson M; Mellor AL; Prendergast GC; Munn DH
    Cancer Res; 2007 Jan; 67(2):792-801. PubMed ID: 17234791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.
    Cho JH; Lee HJ; Ko HJ; Yoon BI; Choe J; Kim KC; Hahn TW; Han JA; Choi SS; Jung YM; Lee KH; Lee YS; Jung YJ
    Oncotarget; 2017 Apr; 8(15):24932-24948. PubMed ID: 28212561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions between TLR7 and TLR9 agonists and receptors regulate innate immune responses by astrocytes and microglia.
    Butchi NB; Du M; Peterson KE
    Glia; 2010 Apr; 58(6):650-64. PubMed ID: 19998480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
    Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
    J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.
    Khong A; Cleaver AL; Fahmi Alatas M; Wylie BC; Connor T; Fisher SA; Broomfield S; Lesterhuis WJ; Currie AJ; Lake RA; Robinson BW
    BMC Cancer; 2014 Dec; 14():969. PubMed ID: 25518732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
    Schafer CC; Wang Y; Hough KP; Sawant A; Grant SC; Thannickal VJ; Zmijewski J; Ponnazhagan S; Deshane JS
    Oncotarget; 2016 Nov; 7(46):75407-75424. PubMed ID: 27705910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly (γ-glutamic acid) based combination of water-insoluble paclitaxel and TLR7 agonist for chemo-immunotherapy.
    Seth A; Heo MB; Lim YT
    Biomaterials; 2014 Sep; 35(27):7992-8001. PubMed ID: 24954733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects.
    Jiang X; Li X; Zheng S; Du G; Ma J; Zhang L; Wang H; Tian J
    Int J Immunopathol Pharmacol; 2020; 34():2058738420950584. PubMed ID: 32962460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.
    Holmgaard RB; Zamarin D; Munn DH; Wolchok JD; Allison JP
    J Exp Med; 2013 Jul; 210(7):1389-402. PubMed ID: 23752227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice.
    Koga-Yamakawa E; Murata M; Dovedi SJ; Wilkinson RW; Ota Y; Umehara H; Sugaru E; Hirose Y; Harada H; Jewsbury PJ; Yamamoto S; Robinson DT; Li CJ
    Cancer Immunol Immunother; 2015 Oct; 64(10):1229-39. PubMed ID: 26091797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice.
    Huang SW; Chen YJ; Wang ST; Ho LW; Kao JK; Narita M; Takahashi M; Wu CY; Cheng HY; Shieh JJ
    J Dermatol Sci; 2016 Oct; 84(1):59-70. PubMed ID: 27449383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT.
    Ou X; Cai S; Liu P; Zeng J; He Y; Wu X; Du J
    J Cancer Res Clin Oncol; 2008 May; 134(5):525-33. PubMed ID: 17909857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imiquimod attenuates the growth of UVB-induced SCC in mice through Th1/Th17 cells.
    Yokogawa M; Takaishi M; Nakajima K; Kamijima R; Digiovanni J; Sano S
    Mol Carcinog; 2013 Oct; 52(10):760-9. PubMed ID: 22431065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.